Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Amino Acid > Trastuzumab

Trastuzumab

Trastuzumab is a monoclonal antibody used in the treatment of certain types of breast cancer.
It targets the HER2 protein, which is overexpressed in some breast cancers, and can help slow or stop the growth of these tumors.
Trastuzumab is often used in combination with other chemotherapy drugs and has been shown to improve outcomes for patients with HER2-positive breast cancer.
Researchers can use PubCompare.ai to optimize their Trastuzumab research by locating relevant protocols from the literature, pre-prints, and patents, and identifying the best approaches using the platform's powerful AI-driven comparison and optimization tools.
This can enhance reproducibility and accuracy in Trastuzumab studies.

Most cited protocols related to «Trastuzumab»

1
Neoadjuvant Anti-HER2 Therapy Trial
Cited 16 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2012
Biopharmaceuticals Bone Marrow Breast Breast Neoplasm Echocardiography ERBB2 protein, human Ethics Committees Heart Inflammatory Breast Carcinoma Kidney Lapatinib Malignant Neoplasm of Breast Mammography Neoplasm Metastasis Neoplasms Paclitaxel Patients Radionuclide Imaging Thoracic Surgical Procedures Trastuzumab Ultrasonography Ventricular Ejection Fraction Woman
2
T-DM1 vs. Lapatinib plus Capecitabine in HER2+ Breast Cancer
Cited 15 times
The EMILIA study is a randomized, open-label, international trial involving patients with HER2-positive, unresectable, locally advanced or metastatic breast cancer who were previously treated with trastuzumab and a taxane. The study was conducted in accordance with the International Conference on Harmonization Good Clinical Practice standards and the Declaration of Helsinki. Patients provided written informed consent; the study was approved by the relevant institutional review board or independent ethics committee.
Patients were randomly assigned in a 1:1 ratio to T-DM1 or lapatinib plus capecitabine with the use of a hierarchical, dynamic randomization scheme through an interactive voice-response system. Stratification factors were world region (United States, Western Europe, or other), the number of prior chemotherapy regimens for unresectable, locally advanced or metastatic disease (0 or 1 vs. >1), and disease involvement (visceral vs. nonvisceral).
The primary end points were progression-free survival assessed by independent review, overall survival, and safety. Progression-free survival was defined as the time from randomization to progression or death from any cause. Progression was assessed according to modified Response Evaluation Criteria in Solid Tumors (RECIST), version 1.012 (link); the modified criteria are specified in the Supplementary Appendix, available with the full text of this article at NEJM.org. Overall survival was defined as the time from randomization to death from any cause. Prespecified secondary end points included progression-free survival (investigator-assessed), the objective response rate, the duration of response, and the time to symptom progression. The objective response rate was determined according to modified RECIST on the basis of an independent review of patients with measurable disease at baseline; responses were confirmed at least 28 days after the initial documentation of a response. The time to symptom progression was defined as the time from randomization to the first decrease of 5 points or more from baseline scores on the Trial Outcome Index of the patient-reported Functional Assessment of Cancer Therapy–Breast (FACT-B TOI, on which scores range from 0 to 92, with higher scores indicating a better quality of life)13 (link) in women with a baseline score and at least one postbaseline score. Safety was monitored by an independent data monitoring committee and a cardiac review committee.
Verma S., Miles D., Gianni L., Krop I.E., Welslau M., Baselga J., Pegram M., Oh D.Y., Diéras V., Guardino E., Fang L., Lu M.W., Olsen S, & Blackwell K. (2012). Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. The New England journal of medicine, 367(19), 1783-1791.
Publication 2012
Breast Capecitabine Conferences Disease Progression ERBB2 protein, human Ethics Committees Ethics Committees, Research Heart Lapatinib Malignant Neoplasm of Breast Patients Pharmacotherapy Safety taxane Therapeutics Trastuzumab Treatment Protocols Woman
3
Adjuvant Trastuzumab Therapy for HER2-Positive Breast Cancer
Cited 15 times
From April 2001 through March 2004, we randomly assigned 3222 women with HER2-positive, invasive, high-risk, node-negative or node-positive adenocarcinoma (stage T1, T2, or T3) from 41 countries to receive a standard adjuvant anthracycline–taxane chemotherapy regimen, the same regimen plus trastuzumab, or a new non-anthracycline, trastuzumab-based regimen (Fig. 1 in the Supplementary Appendix, available with the full text of this article at NEJM.org). Specific demographic and clinical characteristics of patients were similar in the three study groups (Table 1). The HER2-positive status of all tumors was confirmed with the use of fluorescence in situ hybridization (PathVision, Abbott) before randomization.
In the first group, women received standard therapy with doxorubicin (60 mg per square meter) and cyclophosphamide (600 mg per square meter) every 3 weeks for four cycles, followed by docetaxel (100 mg per square meter) every 3 weeks for four doses (AC-T). In the second group, patients received AC-T plus trastuzumab, beginning with the first dose of docetaxel and continuing for 1 year (AC-T plus trastuzumab). In the third group, patients received docetaxel (75 mg per square meter) plus carboplatin (area under the curve, 6 mg per milliliter per minute), given every 3 weeks for six cycles concurrently with trastuzumab, followed by trastuzumab for an additional 34 weeks (TCH). In the two trastuzumab-containing regimens, trastuzumab was initially administered at a dose of 4 mg per kilogram of body weight, followed by 2 mg per kilogram per week during chemotherapy and then 6 mg per kilogram every 3 weeks to complete 1 year of trastuzumab treatment. Hematopoietic growth factors were used at the discretion of treating physicians.
The institutional review board at each institution approved the study. All patients provided written informed consent.
Slamon D., Eiermann W., Robert N., Pienkowski T., Martin M., Press M., Mackey J., Glaspy J., Chan A., Pawlicki M., Pinter T., Valero V., Liu M.C., Sauter G., von Minckwitz G., Visco F., Bee V., Buyse M., Bendahmane B., Tabah-Fisch I., Lindsay M.A., Riva A, & Crown J. (2011). Adjuvant Trastuzumab in HER2-Positive Breast Cancer. The New England Journal of Medicine, 365(14), 1273-1283.
Publication 2011
Adenocarcinoma Anthracyclines Body Weight Carboplatin Chemotherapy, Adjuvant Cyclophosphamide Docetaxel Doxorubicin ERBB2 protein, human Ethics Committees, Research Fluorescent in Situ Hybridization Hematopoietic Cell Growth Factors Neoplasms Patients Pharmacotherapy Physicians taxane Trastuzumab Treatment Protocols Woman
4
Molecular Profiling of Metastatic Gastrointestinal Cancers
Cited 14 times
Patients with metastatic esophageal, gastric, and gastroesophageal junction adenocarcinoma receiving therapy at Memorial Sloan Kettering Cancer Center (MSK) were consented to an institutional review board approved protocol for prospective tumor genomic profiling between February 2014 and February 2017. The studies were conducted in accordance with the Declaration of Helsinki, International Ethical Guidelines for Biomedical Research Involving Human Subjects (CIOMS), Belmont Report, or U.S. Common Rule.
All tumors were prospectively reviewed to confirm histologic subtype, Lauren classification, and to estimate tumor content. Of 376 tumors submitted for sequencing, 318 samples were included in the final analysis (see CONSORT diagram in Supplementary Figure 4). We integrated genomic data with clinical characteristics, treatment history, response, and survival data (as of September 2017). Overall survival (OS) time was measured from the date of diagnosis of Stage IV disease until the date of death or last follow-up. Progression-free survival (PFS) and OS on first-line platinum therapy and first-line chemotherapy with trastuzumab and immune checkpoint inhibitors in chemotherapy-refractory patients was calculated from the date of start of treatment to the date of radiographic disease progression, death or last evaluation. Clinical HER2 status was based on HER2 protein expression by immunohistochemistry (IHC, positive defined as 3+) or ERBB2 gene amplification by FISH using College of American Pathologists (CAP)/American Society of Clinical Oncology (ASCO) criteria. IHC analysis of mismatch repair (MMR) proteins, and beta 2 microglobulin (B2M), and Epstein-Barr encoding region (EBER) in situ hybridization analysis was performed on a subset of tumors from patients treated with checkpoint inhibitors.
The MSK-IMPACT assay was performed in a CLIA-certified laboratory, initially using a 341 and more recently 410 and 468 gene panels (Supplementary Table 5), as previously described, with results reported in the electronic medical record (12 (link),31 (link)). The assay is capable of detecting mutations, small insertions and deletions, copy number alterations and select structural rearrangements. In a previously published validation set, ERBB2 amplification calls on this NGS assay had an overall concordance of 98.4% with the combined IHC/FISH results (20 (link)). The PPV and NPV of our NGS assay with respect to HER2 IHC/FISH was calculated in this cohort.
Tumors were assigned to consensus TCGA molecular subtypes: CIN, GS, EBV, MSI-H (3 (link)). We assessed tumors for microsatellite instability (MSI) using the MSI-sensor method, and samples with a score >=10 were classified as MSI-high (MSI-H). Tumors were characterized as genomically stable (GS) if the fraction of the autosomal genome affected by DNA copy number alterations of any kind (FGA) was less than 5%. We classified tumors that were neither EBV-positive, MSI, or GS as CIN (chromosomal instability). The OncoKB Precision Oncology Knowledge Base was used (data from May 2017) (14 ) to infer the oncogenic effect and clinical actionability of individual somatic mutations. Recurrent mutational hotspots were annotated using cancerhotspots.org (32 (link)). We inferred allele-specific DNA copy number using FACETS (33 (link)) to determine the zygosity of key mutant tumor suppressors as well as to generate estimates of tumor purity. We also inferred large-scale state transition (LST) scores (34 (link)), based on the copy number data, from tumors with an analytically estimated tumor purity greater than 20%. Samples with <20% tumor content were excluded from the analysis.
Janjigian Y.Y., Sanchez-Vega F., Jonsson P., Chatila W.K., Hechtman J.F., Ku G.Y., Riches J.C., Tuvy Y., Kundra R., Bouvier N., Vakiani E., Gao J., Heins Z.J., Gross B.E., Kelsen D.P., Zhang L., Strong V.E., Schattner M., Gerdes H., Coit D.G., Bains M., Stadler Z.K., Rusch V.W., Jones D.R., Molena D., Shia J., Robson M.E., Capanu M., Middha S., Zehir A., Hyman D.M., Scaltriti M., Ladanyi M., Rosen N., Ilson D.H., Berger M.F., Tang L., Taylor B.S., Solit D.B, & Schultz N. (2017). Genetic predictors of response to systemic therapy in esophagogastric cancer. Cancer discovery, 8(1), 49-58.
Publication 2017
Adenocarcinoma Alleles BETA MICROGLOBULIN 2 Biological Assay Cell Cycle Checkpoints Chromosomal Instability Copy Number Polymorphism Diagnosis Diploid Cell Disease Progression ERBB2 protein, human Esophagogastric Junction Ethics Committees, Research Fishes Gene Amplification Gene Deletion Gene Rearrangement Genes Genome Immune Checkpoint Inhibitors Immunohistochemistry inhibitors Insertion Mutation In Situ Hybridization Malignant Neoplasms Microsatellite Instability Mismatch Repair Mutation Neoplasms Oncogenes Pathologists Patients Pharmacotherapy Platinum Proteins Stomach Trastuzumab Tumor Suppressor Genes X-Rays, Diagnostic
5
Xenograft Tumor Transplant for Drug Evaluation
Cited 12 times
Fresh xenograft tumor fragments of selected xenograft lines were transplanted into the cleared fat pad of recipient mice. When tumors reached a volume of ~200 mm3, mice were randomized and treated with either vehicle (9-10 mice), a single intraperitoneal injection of Docetaxel (20mg/kg) (3-9 mice), a single intraperitoneal injection of Doxorubicin (3mg/kg) (3-9 mice), or combined Trastuzumab and Lapatinib (10 mice) as described [30 (link), 31 (link)], depending on the treatment the patient of origin received clinically. In some cases, patients were treated with chemotherapy in combination with an experimental targeted therapeutic (e.g. Dasatinib or a gamma secretase inhibitor). In such cases, resistance to both agents in the patient, and resistance to single agent in the xenograft were considered concordant. Tumor size was monitored twice weekly using calipers for a period of at least 2 weeks, and growth curves plotted. Sensitivity was defined as ≥30% regression (RECIST partial response or complete response); Resistance was defined as either <30% regression, stable disease, or continued growth (RECIST stable disease or progressive disease). Treatment responses in xenografts were compared to those of the primary tumor for concordance, and statistical significance of the difference between observed and expected concordance was evaluated by Fisher’s Exact Test. The degree of concordance above that expected by chance was evaluated using the kappa statistic.
Zhang X., Claerhout S., Pratt A., Dobrolecki L.E., Petrovic I., Lai Q., Landis M.D., Wiechmann L., Schiff R., Giuliano M., Wong H., Fuqua S.W., Contreras A., Gutierrez C., Huang J., Mao S., Pavlick A.C., Froehlich A.M., Wu M.F., Tsimelzon A., Hilsenbeck S.G., Chen E.S., Zuloaga P., Shaw C.A., Rimawi M.F., Perou C.M., Mills G.B., Chang J.C, & Lewis M.T. (2013). A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-derived Human Breast Cancer Xenograft (PDX) Models. Cancer research, 73(15), 4885-4897.
Publication 2013
Dasatinib Docetaxel Doxorubicin gamma-Secretase Heterografts Hypersensitivity Injections, Intraperitoneal Lapatinib Mus Neoplasms Pad, Fat Patients Pharmacotherapy Transplant Recipients Trastuzumab

Most recents protocols related to «Trastuzumab»

1
Bivalent Binding of HER2 Inhibits Proliferation
Not available on PMC !

Example 8

Binding of trastuzumab to overexpressed HER2 in HER2 amplified cancer cells results in robust interference of constitutive ligand independent PI3K signaling initiated by the deregulated HER2-HER3 complex (Junttila et al. Cancer Res. 74(19): 5561-5571, 2014). The 1Fab-IgG TDB molecule binds to HER2 in bivalent form. In vitro treatment of SKBR3 cells with incubation with 1Fab-IgG TDB resulted in transient non-durable reduction of pAKT, without detectable effect on HER3 phosphorylation (FIG. 28A). In addition, neither monovalent high HER2 affinity IgG TDB, nor bivalent low HER2 affinity 1Fab-IgG TDB substantially affected the proliferation/viability of SKBR3 cells (FIG. 28B). In summary, bivalent low affinity binding to HER2 does not inhibit proliferation of HER2-amplified cells.

US11866498B2. Bispecific antigen-binding molecules and methods of use (2024-01-09). Genentech, Inc. [US]. Inventors: Diego Ellerman [US], Teemu T. Junttila [US], Twyla Noelle Lombana [US], Dionysos Slaga [US], Christoph Spiess [US].
Full text: Click here
Patent 2024
Cardiac Arrest Cell Proliferation Cells Cell Survival erbB-3, Proto-Oncogene Proteins ERBB2 protein, human Ligands Malignant Neoplasms Phosphorylation PIK3CB protein, human Thomsen-Friedenreich antibodies Transients Trastuzumab
2
Non-Inferiority Cardiac Surveillance in HER2+ Breast Cancer
The proportion of patients who develop a cardiac event at 12 months will be estimated together with an exact 95% confidence interval. Based upon our preliminary data of early-stage HER2-positive patients treated with non-anthracycline trastuzumab-based regimens, the estimated cardiac event rate is 1.2% (95% CI 0.1–4.1%) [21 ]. The null hypothesis of the current study is that a reduced cardiotoxicity surveillance strategy is non-inferior to routine standard-of-care surveillance by a prespecified margin in the cardiac event rate of 2.9%. This non-inferiority margin corresponds to the difference between the observed cardiac event rate from our preliminary data and the upper bound of the 95% confidence interval. With 190 patients, we will have 84% power to reject the null hypothesis using a one-sided exact test with a significance level of 0.052. We will reject the null hypothesis if no more than 3 participants develop a cardiac event. If 4 or more cardiac events are observed during any point in the trial, the study will stop.
Yu A.F., Dang C.T., Jorgensen J., Moskowitz C.S., DeFusco P., Oligino E., Oeffinger K.C., Liu J.E, & Steingart R.M. (2023). Rationale and design of a cardiac safety study for reduced cardiotoxicity surveillance during HER2-targeted therapy. Cardio-oncology, 9, 13.
Full text: Click here
Publication 2023
Anthracyclines Cardiac Events Cardiotoxicity ERBB2 protein, human Patients Rate, Heart Trastuzumab Treatment Protocols
3
Cardiac Safety in HER2+ Breast Cancer
The study will be conducted in HER2-positive breast cancer patients (stage I-IV) receiving a non-anthracycline-based chemotherapy regimen in combination with a HER2-targeted agent (e.g. trastuzumab, pertuzumab, or ado-trastuzumab emtansine). The primary exclusion criteria are: (1) prior treatment with anthracyclines or HER2-targeted therapy; (2) baseline LVEF < 53% (or institutional lower limit of normal); (3) systolic or diastolic blood pressure ≥ 160 mmHg or ≥ 90 mmHg, respectively; and (4) history of heart failure, cardiomyopathy, or other significant CVD associated with increased cardiotoxicity risk (e.g. atrial fibrillation, atherosclerotic cardiovascular disease, significant valvular heart disease, etc.). Following approval by the primary medical oncologist, written informed consent will be obtained from each patient prior to study enrollment. The inclusion and exclusion criteria of this study are presented in Table 1.

Main eligibility criteria

Inclusion criteriaExclusion criteria

1. Female

2. Age ≥ 18 years

3. Pathologically confirmed HER2-positive invasive breast carcinoma (stage I-IV)

4. Anticipated treatment with HER2-targeted therapy for ≥ 12 months

5. Normal LV systolic function (LVEF ≥ institutional lower limit of normal)

6. Willing and able to provide written informed consent and comply with the requirements of the protocol

1. Anticipated treatment with anthracycline chemotherapy

2. Prior treatment with anthracycline chemotherapy

3. History of cardiomyopathy, heart failure, or other clinically significant cardiovascular disease

4. Uncontrolled hypertension, defined as a systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 90 mmHg

Yu A.F., Dang C.T., Jorgensen J., Moskowitz C.S., DeFusco P., Oligino E., Oeffinger K.C., Liu J.E, & Steingart R.M. (2023). Rationale and design of a cardiac safety study for reduced cardiotoxicity surveillance during HER2-targeted therapy. Cardio-oncology, 9, 13.
Full text: Click here
Publication 2023
Ado-Trastuzumab Emtansine Anthracyclines Atherosclerosis Atrial Fibrillation Breast Carcinoma Cardiomyopathies Cardiotoxicity Cardiovascular System Combination Drug Therapy Congestive Heart Failure Eligibility Determination erbb2 Gene High Blood Pressures Malignant Neoplasm of Breast Oncologists Patients pertuzumab Pressure, Diastolic Systole Systolic Pressure Trastuzumab Treatment Protocols Valve Disease, Heart
4
Investigating Ab Framework Mutations
To understand the role of framework mutations on Ab structure and dynamics, we investigated the behavior of the fragment antigen-binding (Fab) region of five mature Abs (Atezolizumab, Daratumumab, Omalizumab, Pertuzumab, and Trastuzumab) both with and without GL-reverting mutations (herein, referred to as control Abs). This allowed us to parse out the effects of key single- and double-point mutations along the evolutionary trajectories of the clinically-relevant Abs of interest. Mutations are annotated throughout the text using the IMGT numbering scheme (e.g., X100Y, where X mutates to Y). The mutations were chosen based upon our previously-published (12 (link)) position specific scoring matrix (PSSM) for human Ab repertoires (Table S1), and were selected to include both high and low probabilities in the PSSM as well as a range of amino acid types.
Rhodes E.R., Faris J.G., Petersen B.M, & Sprenger K.G. (2023). Common framework mutations impact antibody interfacial dynamics and flexibility. Frontiers in Immunology, 14, 1120582.
Full text: Click here
Publication 2023
Amino Acids atezolizumab Biological Evolution daratumumab Homo sapiens Immunoglobulins, Fab Mutation Omalizumab pertuzumab Point Mutation Trastuzumab
5
Retrospective Study of HER2+ Gastroesophageal Cancer
The model was designed in a training cohort that included patients from the AGAMENON oesophageal and gastric cancer registry managed by the SEOM in which 42 Spanish university hospitals participate. The characteristics of this registry, quality criteria, methods and data collection criteria have been described previously.17 (link)–20 (no link found, no link found, link) To comprehend the representativeness of the data, Supplemental Annex Table 1 contains a description of all the centres that are participating in the registry.
Patients eligible for this study were adults (age ⩾18 years), diagnosed with locally advanced or metastatic unresectable adenocarcinoma of the distal oesophagus, GEJ and stomach, HER2+ who received at least one cycle of chemotherapy and trastuzumab as first-line treatment. HER2 status was studied locally at the centres and defined as IHC 3+ or IHC 2+/FISH+. Subjects who had completed perioperative or adjuvant systemic treatment in the previous 6 months and those with HER2+ cancers that were not treated with first-line trastuzumab were excluded.
Data were collected from medical records or directly from the patient by medical oncologists experienced in treating AGA and trained to meet the requirements of the study via an online platform. This tool includes real-time alerts to avoid inconsistencies, unjustified missing values and errors, and regular telephone and online monitoring is performed. Patient-reported outcome measures were not collected.
Results were externally validated in a separate cohort from The Christie NHS Foundation Trust (Manchester, UK), which included consecutive patients who met the same eligibility criteria.
Jimenez-Fonseca P., Foy V., Raby S., Carmona-Bayonas A., Macía-Rivas L., Arrazubi V., Cacho Lavin D., Hernandez San Gil R., Custodio A., Cano J.M., Fernández Montes A., Mirallas O., Macias Declara I., Vidal Tocino R., Visa L., Limón M.L., Pimentel P., Martínez Lago N., Sauri T., Martín Richard M., Mangas M., Gil Raga M., Calvo A., Reguera P., Granja M., Martín Carnicero A., Hernández Pérez C., Cerdá P., Gomez Gonzalez L., Garcia Navalon F., Pacheco Barcia V., Gutierrez Abad D., Ruiz Martín M., Weaver J., Mansoor W, & Gallego J. (2023). The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy. Therapeutic Advances in Medical Oncology, 15, 17588359231157641.
Publication 2023
Adenocarcinoma Of Esophagus Adult Eligibility Determination ERBB2 protein, human Esophagus Fishes Gastric Cancer Hispanic or Latino Malignant Neoplasms Oncologists Patients Pharmaceutical Adjuvants Pharmacotherapy Stomach Trastuzumab

Top products related to «Trastuzumab»

1
Trastuzumab by Roche
Sourced in Switzerland, Germany, United States, China, United Kingdom
Trastuzumab is a monoclonal antibody used in laboratory research. It functions by specifically targeting the HER2/neu protein, which is expressed on the surface of certain types of cancer cells.
2
Trastuzumab by Genentech
Sourced in United States, Cameroon
Trastuzumab is a monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2) protein. It is used in the detection and quantification of HER2 expression in various cell and tissue samples.
3
Herceptin by Roche
Sourced in Switzerland, Germany, China, Canada, France, United States, United Kingdom
Herceptin is a laboratory product manufactured by Roche. It is a monoclonal antibody used for research and analytical purposes in laboratory settings.
4
Herceptin by Genentech
Sourced in United States, Cameroon
Herceptin is a laboratory instrument used for cell culture and protein expression. It is a monoclonal antibody that targets the HER2 receptor protein. The core function of Herceptin is to bind to and block the HER2 receptor, which is involved in the growth and division of cancer cells.
5
Skbr3 by American Type Culture Collection
Sourced in United States, Germany, United Kingdom, China, Sweden, France, Italy, Japan
SKBR3 is a cell line derived from a breast adenocarcinoma. It is a commonly used model for breast cancer research.
6
Bt474 by American Type Culture Collection
Sourced in United States, Germany, United Kingdom, Japan, Sweden
The BT474 is a cell line derived from a human breast carcinoma. It is a well-characterized model for studying breast cancer biology and is commonly used in research and drug development.
7
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
8
Sephadex g 25 by GE Healthcare
Sourced in United States, Sweden, United Kingdom, Germany, Japan
Sephadex® G-25 is a gel filtration medium used in size exclusion chromatography. It is a cross-linked dextran-based material that separates molecules based on their size and molecular weight. Sephadex® G-25 is commonly used for desalting, buffer exchange, and sample clean-up applications.
9
Facscalibur by BD
Sourced in United States, Germany, United Kingdom, China, Canada, Japan, Italy, France, Belgium, Singapore, Uruguay, Switzerland, Spain, Australia, Poland, India, Austria, Denmark, Netherlands, Jersey, Finland, Sweden
The FACSCalibur is a flow cytometry system designed for multi-parameter analysis of cells and other particles. It features a blue (488 nm) and a red (635 nm) laser for excitation of fluorescent dyes. The instrument is capable of detecting forward scatter, side scatter, and up to four fluorescent parameters simultaneously.
10
Lapatinib by Selleck Chemicals
Sourced in United States, China, Germany
Lapatinib is a synthetic organic compound used as a laboratory reagent. It functions as a tyrosine kinase inhibitor, specifically targeting the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) proteins.

More about "Trastuzumab"

Trastuzumab, also known as Herceptin, is a monoclonal antibody used in the treatment of certain types of breast cancer.
It targets the HER2 (human epidermal growth factor receptor 2) protein, which is overexpressed in some breast cancers, and can help slow or stop the growth of these tumors.
Trastuzumab is often used in combination with other chemotherapy drugs and has been shown to improve outcomes for patients with HER2-positive breast cancer.
Researchers can utilize the powerful AI-driven comparison and optimization tools provided by PubCompare.ai to enhance their Trastuzumab research.
This platform allows researchers to locate relevant protocols from the literature, pre-prints, and patents, and identify the best approaches for their studies.
By using PubCompare.ai, researchers can improve the reproducibility and accuracy of their Trastuzumab research.
The HER2 protein is a key target for Trastuzumab, and it is often overexpressed in breast cancer cell lines such as SKBR3 and BT474.
Researchers may use these cell lines, along with fetal bovine serum (FBS) and Sephadex® G-25 columns, to conduct experiments related to Trastuzumab's mechanism of action and its effects on cancer cell growth and proliferation.
Flow cytometry techniques, such as those using a FACSCalibur instrument, can be employed to analyze the expression of HER2 and other relevant biomarkers.
In addition to Trastuzumab, other targeted therapies like Lapatinib may also be used in the treatment of HER2-positive breast cancer.
Researchers can explore the synergistic effects and combination strategies of these therapies to optimize treatment outcomes for patients.